Evidence map›Paper›PMID 41749748›Full record

ArticleBioengineering (Basel, Switzerland)2026

Lipid-Polymer Nanoparticles (LiPoNs) Mediated Codelivery of AntimiR-21 and Gadolinium Chelate in Triple Negative Breast Cancer Theranostics.

Felicia Roffo, Francesca Maria Orlandella, Neila Luciano, Giuliana Salvatore, Enza Torino

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Felicia RoffoDepartment of Chemical, Materials and Production Engineering (DICMaPI), University of Naples Federico II, P.le Tecchio 80, 80125 Naples, Italy.
Francesca Maria OrlandellaDepartment of Medical, Human Movement and Well-Being Sciences, University of Naples Parthenope, 80133 Naples, Italy.
Neila LucianoDepartment of Medical, Human Movement and Well-Being Sciences, University of Naples Parthenope, 80133 Naples, Italy.ORCID 0000-0002-5239-2910
Giuliana SalvatoreDepartment of Medical, Human Movement and Well-Being Sciences, University of Naples Parthenope, 80133 Naples, Italy.
Enza TorinoDepartment of Chemical, Materials and Production Engineering (DICMaPI), University of Naples Federico II, P.le Tecchio 80, 80125 Naples, Italy.ORCID 0000-0002-8905-1925

Funding

MUR 2022BFF2CJ
6 · The paper itself

Abstract

RNA-based interventions are particularly promising for next-generation therapeutic strategies and hold significant potential when integrated with diagnostic modalities. Among noncoding RNAs, microRNAs (miRNAs) regulate gene expression post-transcriptionally and represent compelling targets for cancer therapy. However, their clinical translation remains hindered by instability, off-target effects, and limited delivery efficiency. Here, we report the microfluidic synthesis of hybrid lipid-polymer nanoparticles (LiPoNs) that co-deliver an AntimiR-21 and the magnetic resonance imaging contrast agent gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA). The LiPoNs were obtained using coupled Hydrodynamic Flow Focusing (cHFF), enabling precise control over lipid-polymer self-assembly and surpassing the compositional limitations reported with conventional micromixers. The resulting AntimiR-21-Gd-DTPA-LiPoNs exhibited an average hydrodynamic diameter of 124 nm, narrow polydispersity (PDI < 0.2), and encapsulation efficiency up to 60%. In MDA-MB-231 breast cancer cells, treatment with AntimiR-21-LiPoNs induced suppression of miR-21 and a corresponding decrease in migratory capacity, demonstrating effective functional delivery and gene expression modulation. These findings establish a versatile microfluidic platform for engineering multifunctional lipid-polymer nanostructures whose hybrid architecture combines the biocompatibility and membrane fusion capability of lipids with the structural robustness and controlled release properties of polymers, thereby advancing RNA-based theranostic design for precision oncology and related applications.

Indexed as

chitosanhybrid lipid–polymer nanoparticlesmicroRNA

Identifiers

PMID41749748
PMCPMC12938064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.